GlassScriptPhysician profile
Claudia Vogel
NPI 1730161191
$12,040.82
in general payments reported to CMS, 2019-2025
55 companies · $1,179 in 2025
The $1,179 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,299 · 2020: $623 · 2021: $2,279 · 2022: $3,893 · 2023: $1,158 · 2024: $1,610 · 2025: $1,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,933 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,932.62 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,263.25 | 2021-2024 | Intellis Adaptivestim, Vanta Adaptivestim, Minimed 780g |
| Nevro Corp. | $1,477.07 | 2019-2022 | |
| Corcept Therapeutics | $830.07 | 2019-2025 | Korlym |
| Novo Nordisk INC | $786.83 | 2019-2025 | Ozempic, Rybelsus |
| Boston Scientific Corporation | $540.20 | 2024-2025 | Intracept |
| Recordati_rare_diseases_inc. | $453.86 | 2021-2025 | Isturisa, Signifor Lar |
| Averitas Pharma INC. | $419.14 | 2023-2025 | Qutenza |
| Abbott Laboratories | $395.04 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.50 | 2019-2025 | Jardiance |
| Abbvie INC. | $329.25 | 2020-2025 | Rinvoq |
| Radius Health, INC. | $325.00 | 2019-2025 | Tymlos |
| Amgen INC. | $296.42 | 2019-2025 | Otezla, Repatha, Tepezza |
| Grt US Holding, INC. | $284.49 | 2021-2022 | |
| Horizon Therapeutics Plc | $219.33 | 2022-2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $217.93 | 2022-2024 | Recorlev, Gvoke Hypopen |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Vogel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.